CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReadCoor, Inc., a company leading true multi-omic spatial sequencing, today unveils its first product line, including multi-omic spatial sequencing assays and the RC2 instrument. The platform is powered by ReadCoor’s proprietary FISSEQ (Fluorescent in situ Sequencing) technology, which combines the massive multiplexity of next-generation sequencing (NGS) and high-resolution tissue imaging. The fully integrated platform is now available for use by researchers through ReadCoor’s Select Release Program (SRP), focusing on initial applications in immuno-oncology, neuroscience, and infectious disease, as well as a custom offering. ReadCoor has increased its Series B investment round to $30 million to accelerate commercial efforts.
The new platform simultaneously detects tens to thousands of RNA and DNA sequences, proteins, and therapeutic molecules at nanoscale 3D resolution in every cell within an intact tissue sample. The key products launched today are:
- Automated, turn-key spatial sequencing instrument called RC2 that captures sub-cellular complexity at nanoscale resolution across entire tissue sections.
-
Application Kits containing all components necessary to prepare tissue samples for spatial sequencing on the RC2 in a single sample processing workflow.
- Sample slides provide optimized surfaces compatible with standard sectioning workflows for FFPE, fixed frozen, or fresh frozen tissues and feature markings to guide tissue placement.
- Instrument Kits contain all necessary bulk and sequencing reagents to collect spatial sequencing information from up to four tissue samples per run.
- Analysis and Visualization Cloudware that fully integrates data management and analysis. Users can manage and analyze sub-cellular molecular information with visualization tools that display molecular and morphological volumes, display locations for all multi-omic targets in 3D, select regions of interest, and employ spatial statistical methods for unbiased discovery.
“We firmly believe our true multi-omic sequencing technology will have a dramatic impact on medicine and healthcare, and this motivates us to provide researchers products that offer unprecedented and meaningful insights into human biology,” said Richard Terry, Chief Executive Officer, Chief Technical Officer, and Founder of ReadCoor. “Our Select Release Program serves as the foundation for researchers to develop new therapeutics and treatments to ultimately improve patient care.”
Users within the SRP can use ReadCoor’s initial applications to support their specific research interests. The applications offer the following capabilities:
-
Immuno-oncology
ReadCoor’s immuno-oncology application unifies disparate histological and molecular assays, eliminating the need to allocate precious tumor samples between anatomical and molecular pathology methods. This approach could increase the efficacy of IO treatments for meaningful clinical insights in immuno-oncology, pathology, and drug discovery. -
Neuroscience
Comprehensive cell function and phenotyping to atlas the brain using the RC2 platform will have enormous benefits to both basic neuroscience research and biomedical applications such as understanding and treating traumatic brain injury and neurodegenerative diseases. -
Infectious Disease
ReadCoor's initial infectious disease application is designed to advance understanding of HIV biology. This approach has the potential to provide insights into many aspects of HIV’s lifecycle and ultimately inform better treatment options towards eradicating this disease.
About ReadCoor, Inc.
ReadCoor is a technology company offering the first true spatial multi-omic platform to the global audience of researchers, clinicians, pharma and diagnostics companies to expand understanding of human biology and facilitate the creation of new therapeutics for patients. The company’s RC2 platform simultaneously detects and reads the sequences of tens to thousands of RNA, DNA, proteins and therapeutics and visualizes sub-cellular nanoscale 3D resolution in every cell throughout any tissue section. The platform is based on ReadCoor’s proprietary Fluorescent in situ Sequencing (FISSEQ) technology, which combines the massive multiplexity of next generation sequencing (NGS) and high-resolution tissue imaging. Learn more at www.readcoor.com.
